CoreCivic, Inc. (CXW) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a positive sentiment with strong financial performance, optimistic guidance, and strategic plans for share repurchases. The Q&A section reveals confidence in ICE population growth and CSP's expansion potential. While there are concerns about ICE ownership timelines and facility conversions, the overall outlook is optimistic. With a market cap of $1.36 billion, the stock is likely to react positively to these developments, resulting in a 2% to 8% increase.
Key Financial Performance
Total Occupancy for Safety and Community Segments 79.6%, up 2.6 points year-over-year. This increase was driven by more demand for services, new contracting activity, and the Farmville acquisition completed on July 1, 2025.
Average Daily Population 57,243 individuals during Q1 2026 compared to 51,429 in Q1 2025, an increase driven by higher demand, new contracts, and the Farmville acquisition.
Revenue from Federal Partners Increased 48% year-over-year in Q1 2026. Revenue from ICE increased by $128.1 million or 96.2%, while revenue from the U.S. Marshals Service decreased by $12.2 million due to a shift in contract mix and fewer apprehensions at the southern border.
Revenue from State Partners Increased 3.6% year-over-year in Q1 2026, driven by per diem increases and population growth in Georgia, Montana, and Colorado. Excluding a decline in revenue at Trousdale, revenue increased by 5.2%.
Adjusted EPS $0.40 in Q1 2026 compared to $0.23 in Q1 2025, a 74% increase. This was driven by facility activations, the Farmville acquisition, and higher state populations.
Normalized FFO per Share $0.65 in Q1 2026 compared to $0.45 in Q1 2025, a 44% increase. This was due to facility activations, the Farmville acquisition, and higher state populations.
Adjusted EBITDA $110.1 million in Q1 2026 compared to $81 million in Q1 2025, a 36% increase. This was driven by facility activations, the Farmville acquisition, and higher state populations.
Operating Margin for Safety and Community Facilities 24% in Q1 2026 compared to 23.6% in Q1 2025. Excluding employee retention credits, the margin was 23% for both quarters.
Share Repurchase Program 2.3 million shares repurchased in Q1 2026 at a cost of $44.7 million. Since 2022, 28.1 million shares have been repurchased at an aggregate price of $444.2 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Acquisition of Clinical Solutions Pharmacy: CoreCivic acquired Clinical Solutions Pharmacy, a leading provider of mail-order pharmacy services to correctional facilities, for $148 million. This acquisition complements CoreCivic's mission and provides a diversifying revenue stream. CSP serves over 600 correctional facilities across 28 states and fills approximately 60,000 prescriptions daily.
Increased ICE Revenue: Revenue from ICE increased by $128.1 million (96.2%) compared to the prior year, driven by higher demand and new contracts.
State Partner Revenue Growth: Revenue from state partners increased by 3.6%, with notable growth in Georgia, Montana, and Colorado.
Facility Activations: CoreCivic activated five previously idle facilities to meet increased demand, including the Midwest Regional Reception Center, California City Detention Facility, and Diamondback Correctional Facility.
Occupancy Rates: Total occupancy for Safety and Community segments increased to 79.6%, up 2.6 points from the prior year.
Share Repurchase Program: CoreCivic repurchased 2.3 million shares for $44.7 million in Q1 2026, prioritizing shareholder value.
Focus on ICE and State Contracts: CoreCivic is leveraging its idle facilities and pursuing new contracts to meet federal and state demand.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
ICE Population Decline: ICE populations in CoreCivic's care have declined by roughly 3,000 individuals since January 2026, which could impact revenue and operational efficiency. This decline is attributed to temporary and event-specific factors, including a government shutdown and redeployment of ICE agents.
Government Shutdown Impact: The government shutdown centered around Department of Homeland Security funding has disrupted ICE enforcement activities, leading to a significant decrease in detention populations and potential revenue loss.
Legal Challenges for Facility Activation: The Midwest Regional Reception Center faced delays in activation due to legal challenges in obtaining a special use permit, impacting the timing of revenue generation.
U.S. Marshals Service Population Decline: Nationwide populations from the U.S. Marshals Service have declined, partially offsetting revenue increases from ICE. This decline is due to fewer apprehensions at the southern border.
Dependence on Federal Partners: Federal partners, primarily ICE and the U.S. Marshals Service, comprise 58% of CoreCivic's total revenue. Any changes in federal policies or enforcement strategies could significantly impact the company's financial performance.
Idle Facilities and Activation Challenges: Activating idle facilities is resource-intensive and challenging, especially when done simultaneously. This could strain operational resources and delay revenue realization.
Regulatory and Policy Risks: Changes in Department of Homeland Security strategies, such as converting vacant warehouses into detention facilities or acquiring turnkey facilities, could reduce demand for CoreCivic's services.
Economic and Market Uncertainty: The company faces economic uncertainties, including fluctuating demand for detention services and potential changes in government funding priorities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ICE Population Trends: Nationwide ICE detention populations reached historic highs of around 70,800 individuals in late January 2026 but declined by 10,500 by early April 2026 due to temporary factors such as a government shutdown and redeployment of ICE agents. The company expects ICE populations to grow during the second half of 2026.
Facility Activations: The Midwest Regional Reception Center is expected to contribute $0.05 to $0.06 in incremental earnings per share for the remainder of 2026. The company has five remaining idle facilities with 7,066 beds, which may be activated to meet future demand.
Financial Guidance for 2026: Updated guidance includes diluted EPS of $1.51 to $1.61, adjusted diluted EPS of $1.53 to $1.63, FFO per share of $2.58 to $2.68, and adjusted EBITDA of $453.8 million to $461.8 million. The guidance reflects growth from facility activations and the acquisition of Clinical Solutions Pharmacy, partially offset by lower ICE populations.
Acquisition of Clinical Solutions Pharmacy: The acquisition is expected to generate $215 million to $230 million in revenue for 2026 and contribute $0.03 to $0.05 per share, net of interest incurred to finance the acquisition.
Capital Expenditures: The company plans to spend $60 million to $70 million on maintenance capital expenditures, $15 million for other capital expenditures, and $40 million to $45 million for facility activations in 2026.
Share Repurchase Program: The company plans to prioritize cash flows for share repurchases, taking into account stock price, liquidity, and alternative capital deployment opportunities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: During the first quarter of 2026, CoreCivic repurchased 2.3 million shares of its common stock at an aggregate cost of $44.7 million. Since the share repurchase program was authorized in 2022, through March 31, 2026, the company has repurchased a total of 28.1 million shares at an aggregate price of $444.2 million or $15.82 per share. As of March 31, 2026, $255.8 million remained available under the Board authorization for further repurchases. The company plans to continue prioritizing cash flows towards share repurchase, considering factors such as stock price, liquidity, earnings trajectory, and alternative opportunities to deploy capital.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the valuation level considered for the sale of facilities to ICE, and would it be a great scenario with or without a contract?
A:The valuation of facilities is difficult to pinpoint due to the lack of comparable sales. The management considers depreciated replacement cost as a guide for valuation. They would consider selling facilities to ICE, depending on the value derived and the duration of the management contract. ICE's intent to have private sector management of facilities post-sale is expected.
Q:What facility utilization levels are expected by the end of the first half and the end of the year?
A:Facility utilization levels are projected to sustain around current levels through the end of Q2, with sequential growth expected in Q3 and Q4. Specific population numbers were not provided.
Q:What is the implied guidance for Q2 and the ramp-up expected in the second half?
A:Q2 is expected to see a $0.06-$0.07 decline from Q1 due to the absence of employee retention credits and a decline in ICE populations. Sequential increases are expected in the second half, with a potential $450 million run rate excluding Clinical Solutions.
Q:What are the synergies and growth opportunities related to the CSP acquisition?
A:CSP will operate as a stand-alone subsidiary with limited operating synergies. Growth opportunities include leveraging customer relationships, expanding into federal agencies, and maintaining a growth rate potentially twice the 10% CAGR built into guidance for 2026. Revenue synergies and administrative opportunities, such as ERP platform consolidation, are also expected.
Q:What is the acquisition strategy and potential for future acquisitions?
A:The company is opportunistic in acquisitions, prioritizing share repurchases due to undervalued share prices. Future acquisitions would need to be attractively valued and strategically aligned. There are no imminent acquisitions planned, but opportunities for adjacent business expansions will be considered.
Q:Is there potential for further acquisitions in the CSP space to expand into additional states?
A:Yes, there is potential for further acquisitions to expand CSP into additional states. Consolidation within the space is seen as an attractive way to scale the platform.
Q:What is the status of discussions with new states for contracts?
A:Discussions with new states are ongoing, but timelines are variable and depend on state procurement processes and budget cycles. No specific updates or timing were provided.
Q:What is the source of growth in ICE populations in the second half, and what is the expected ramp?
A:Growth in ICE populations in the second half is expected from the ramping of facilities like California City Midwest and Diamondback, as well as a nationwide increase in ICE detention populations. A return to 70,000 nationwide ICE populations would align with the midpoint of guidance.
Q:What is the status of ICE's plans to convert warehouses to detention centers?
A:ICE has made some warehouse purchases, but no new warehouse facilities have been fully built out and ramped. The feasibility and timeline for such conversions remain uncertain.
Q:What are the potential margins on contracts if facilities are sold to ICE and then operated by the company?
A:Margins on such contracts would likely be similar to managed-only contracts, but could vary depending on responsibility for ongoing capital expenditures like roof or HVAC replacements. Pricing would account for these responsibilities.
Q:What are the cross-promotional opportunities with CSP and other business lines?
A:Cross-promotional opportunities exist through leveraging customer relationships and expanding service delivery to include multiple services for the same customers. CSP's technical capabilities and scalable platform provide additional growth potential.
Q:What is the potential market share and growth opportunity for CSP?
A:CSP has significant growth potential, with a market share of around 10%. Growth could come from outsourcing by customers currently self-operating and through consolidation within the space. The aging prison population with complex medical needs also contributes to growth.
Q:What is the company's confidence in the ramp-up of ICE populations post-Q2?
A:The company expects ICE populations to grow in the second half due to strong border and interior enforcement commitments, ongoing funding discussions, and the need for additional capacity. A return to 70,000 nationwide ICE populations is expected to align with guidance.
Q:What is the company's approach to managing expenses if ICE populations do not ramp up?
A:The company can adjust expenses by reducing overtime and variable costs, but maintains full staffing to be prepared for expected growth in ICE populations.
Q:What is the company's stance on ICE's interest in owning facilities and the potential timeline for decisions?
A:ICE's interest in owning facilities is part of a broader strategy for a nationwide network. The timeline for decisions is uncertain, as government processes can vary. The company believes ICE's strategy includes turnkey assets as a critical component.
Q:Review of Unclear Management Responses
A:Management avoided providing specific valuation levels for facilities, exact population numbers for facility utilization, and detailed timelines for new state contracts or ICE's decisions on facility ownership. They also refrained from disclosing CSP's exact growth rate and financial profile, as well as specifics on warehouse conversion timelines and potential margins for contracts post-facility sale to ICE.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CSP
Clinical Solutions
DHS
Director Investor
Facility contract
Investor Relations
Managing Director
Marshals population
SUP
Tennessee
Trousdale
United States
agency
analyst
approval
care individual
center
community
conference
correction detention
decline
discount
facility acquisition
government shutdown
increase demand
individual increase
life
mix ICE
order
partner increase
pharmacy
population individual
progress
reduction
responsibility
state customer
trust
turnkey facility
CXW Transcript
CoreCivic, Inc. (CXW) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary indicates a positive sentiment with strong financial performance, optimistic guidance, and strategic plans for share repurchases. The Q&A section reveals confidence in ICE population growth and CSP's expansion potential. While there are concerns about ICE ownership timelines and facility conversions, the overall outlook is optimistic. With a market cap of $1.36 billion, the stock is likely to react positively to these developments, resulting in a 2% to 8% increase.
CoreCivic, Inc. (CXW) Q4 2025 Earnings Call Transcript
Positive2-12
The company has strong revenue and EBITDA projections, and an active share repurchase program, which are positive indicators. The Q&A revealed confidence in staffing and liquidity, despite some declines in margins due to facility activations. The potential for significant revenue and EBITDA growth from ICE contracts and the expanded credit facility further support a positive outlook. The market cap suggests a moderate reaction, leading to a 'Positive' sentiment rating.
CoreCivic, Inc. (CXW) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call summary shows strong revenue growth, increased occupancy, and multiple facility activations, supported by significant government funding. The Q&A section highlights positive hiring conditions, strong capital allocation strategies, and optimistic guidance for future revenue and EBITDA growth. Despite some uncertainties in legal matters and vague management responses, the overall sentiment is positive, with favorable financial metrics and strategic initiatives likely to boost the stock price.
CoreCivic, Inc. (CXW) Q2 2025 Earnings Call Transcript
Positive8-11
The earnings call highlights several positive aspects: strong financial guidance, increased demand for CoreCivic's services, and potential for significant revenue growth from activating idle facilities. The Q&A session reveals high confidence in resolving legal issues and meeting demand shifts, although some management responses were unclear. Overall, the anticipation of new contracts, strategic investments in transportation, and the potential for substantial revenue from idle beds contribute to a positive outlook. Given the company's market cap, a positive stock price movement of 2% to 8% is likely over the next two weeks.
CXW Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
